Blood Test May Identify Lung Cancer Patients Likely To Respond To Erlotinib

Testing for the presence of specific cancer protein ‘fingerprints’ in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, especially when other testing methods are unavailable, according to new data presented at the 2nd European Lung Cancer …

Read more:
Blood Test May Identify Lung Cancer Patients Likely To Respond To Erlotinib

ICA Completes Successful Testing at the 11th Annual Integrating the Healthcare Enterprise (IHE) Connectathon 2010

ICA Completes Successful Testing at the 11th Annual Integrating the Healthcare Enterprise (IHE) Connectathon 2010

Original post:
ICA Completes Successful Testing at the 11th Annual Integrating the Healthcare Enterprise (IHE) Connectathon 2010

Is Chancroid (Haemophilus ducreyi) STD? – STD Testing Centers Nashville

Chancroid is a sexually transmitted infectious disease characterized by painful ulcers, bubo formation, and painful inguinal lymphadenopathy. The causative organism, Haemophilus ducreyi, was found by Ducrey in 1889. Chancroid is a sexually transmitted disease. Risky sexual behaviors, such as having more than one partner, increase the risk for chancroid. Chancroid sometimes is called soft chancre to distinguish it from the chancre of syphilis that feels hard to the touch. The ulcer of chancroid also is painful, unlike the ulcer of syphilis that is painless.) The diagnosis of chancroid can be confirmed by a culture of the material from within the ulcer for the bacterium Hemophilus ducreyi .

Chancroid is characterized by a papule that develops into a pustle within two to three days. The pustle becomes an ulcer in a few weeks that appears as a chancre with irregular borders. Chancroid has become resistant to penicillin and tetracycline. Regular doses of erythromycin, trimethoprin, or ciprofloxacin are given for up to 2 weeks. Chancroid is an infection of the genitals that is caused by the bacterium Haemophilus ducreyi . Chancroid is a sexually transmitted disease , which means that it is spread from person to person almost always by sexual contact.

Chancroid is caused by a bacterial infection that produces genital ulcers. Reported cases of chancroid declined steadily from 4,986 cases in 1987 to 143 reported cases in 1999. Chancroid lesions can occur in genital areas that are covered or protected by a latex condom, but may also occur in areas that are not covered or protected by a condom. Latex condoms, when used consistently and correctly, can reduce the risk of chancroid, genital herpes, syphilis, and genital warts, only when the infected areas are covered or protected by the condom. Chancroid is a sexually transmitted infection (STI) which is spread very easily. It is characterized by ulcers and sores on your private parts which can be very painful.

Chancroid is spread by sexual contact with an infected individual. The bacteria are more likely to invade the sexual organs at the point of a pre-existing injury, such as a small cut or scratch. Chancroid is one of the less common STDs, but it is associated with some very painful and serious side effects. If you suspect that you or your partner has become infected with chancroid, it is important to get tested as soon as possible. Chancroid is a bacterial infection caused by the organism Haemophilus ducreyi. It is a disease found primarily in developing countries, there associated with commercial sex workers and their clientele.

Chancroid sores can also develop on the inner genital lips (the labia minora), the perineal area and the inner thighs. The women may experience pain when urinating and having sexual intercourse. Chancroid is easily curable with appropriate antibiotic therapy, although patients with HIV require longer courses of therapy. The true impact of the disease lies in the well-known association of genital ulcer disease with increased transmission rates of HIV and other STDs. Chancroid can be treated with antibiotics. Successful treatment cures the infection, resolves symptoms and prevents transmission to others.

The Impact of Market Participant Assumptions on Goodwill Impairment Testing and the Valuation of Intangible Assets for Purchase Price Allocations

The Impact of Market Participant Assumptions on Goodwill Impairment Testing and the Valuation of Intangible Assets for Purchase Price Allocations

At a recent Nashville Chapter of Financial Executives International meeting, the topics included the complexity involved with measuring fair value under two of the Financial Accounting Standards Boards most recent pronouncements in this area – SFAS No. 141R Business Combinations and SFAS No. 157 Fair Value Measurements. Within the January/February 2007 edition of Financial Executive, there is a table entitled – FEI CEOs Top 10 Financial Reporting Challenges. Three of the ten financial reporting challenges listed in that table were as follows:

fair value measurements

complexity in financial reporting and

business combinations

Fair Value – SFAS
While SFAS No. 157 coherently explains and defines FASB’s use of fair value in the financial literature, it does not ease the burden of financial executives to implement the standards. For example, a great deal of conversation persists regarding market participants, principal markets, most advantageous markets, etc. These concepts are perhaps a little easier to apply when considering financial assets; however, they are more difficult to implement with intangible assets. Further, there are other issues to consider when applying the standards to intangible assets such as the treatment of expected synergies and whether or not to include some or all of those synergies in the valuation of various assets.

Pronouncement

Effective Date

SFAS No. 157 – Fair Value Measurements

Currently effective for financial assets and financial liabilities

Effective for non-financial assets and non-financial liabilities for fiscal years beginning after November 15, 20081

  SFAS No. 141(R) – Business Combinations

Fiscal years beginning on or after December 15, 2008

Market Participants
There are many considerations that must be addressed when applying SFAS No. 141, SFAS No. 142 (dealing with goodwill and annual impairment testing), and SFAS No. 141(R) under the fair value standard defined by SFAS No. 157. SFAS No. 157 defines fair value as an exit price – or how much value could be obtained upon sale of the asset immediately after acquisition by the reporting entity. A key component in measuring the exit price under fair value is the market participant assumption. Market participants are buyers and sellers in the principal (or most advantageous) market for the asset or liability. Market participants generally are:

Independent of the reporting unit;

Knowledgeable about the asset or liability, the transaction and information that is usual and customary;

Able to transact for the asset or liability; and

Willing to transact for the asset or liability.2

While a true marketplace generally does not exist for many of the individual intangible assets that are included in business combinations and sales, the “fair value of the asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. In developing those assumptions, the reporting entity need not identify specific market participants. Rather, the reporting entity should identify characteristics that distinguish market participants generally…”3

Impact of Market Participant Assumption on Goodwill Impairment Testing
One situation in which market participant assumptions frequently impact financial reporting involves goodwill impairment testing. Assume that a group of investors buys a company using the following market participant assumptions identified through a review of public company information:

Projected sales growth;

Projected operating profit margin;

Rate of return for common equity; and

Interest rates.

Further, assume that most companies in the industry are leveraged with interest-bearing debt ranging from 25% to 35% of total invested capital, however, also assume that the investor group funds the transaction with 70% debt rather than the range indicated by market participants. Not increasing the required rate of return to account for this higher leverage and related risk to common equity might cause the buyer to face an impairment of the asset soon after acquisition. This is due to the fact that, under SFAS No. 142 and SFAS No. 157, market participants would be expected to value the asset using a lower debt structure which, all else being equal, will lead to a higher weighted average cost of capital and a lower fair value.

Conclusion
Many auditors already expect management to apply many of the concepts set forth in SFAS No. 157 when valuing intangible assets although that pronouncement is not actually effective for a few more months as it applies to non-financial assets and non-financial liabilities. Clearly, market participant assumptions need to be identified and supported when assigning valuations to intangible assets when acquiring or merging with another company.

The market participant assumptions must be continually evaluated and supported when testing those assets for impairment in subsequent years. While relevant data can be obtained from many sources, it is our experience that auditors prefer support from a sample of public companies. This, of course, can be a time-consuming effort for many financial executives who will look at these issues once a year.

New Guidance On Determination of the Useful Life of Intangible Assets

  On April 25, 2008, the FASB issued Staff Position on Statement No. 142 (FSP FAS 142-3) which provides additional guidance on the determination of useful lives for intangible assets that are accounted for pursuant to SFAS No. 142. With this announcement, the FASB is attempting to improve the consistency between the useful life of a recognized intangible asset and the period of expected cash flows used to measure the fair value of that intangible asset under SFAS No. 141. Further, the FASB addresses whether or not a difference between the (1) useful life of an intangible asset and (2) the period of expected cash flows used to measure the fair value of the asset might be justified.

  It is interesting to note that FSP FAS 142-3 places primary importance on the reporting entity’s historical experience regarding useful lives and secondary reliance upon market participant assumptions in the absence of historical experience. This contrasts with the fair value measurement’s primary focus on market participant assumptions rather than the reporting entity’s own assumptions.

  The FSP provides an example in which market participants would assume that an acquired technology license would contribute to cash flows for three years and the acquiring company should determine the fair value of the acquired asset on that basis. However, the acquiring entity expects to complete next-generation technology within two years that will make the acquired technology license obsolete. While the fair value should be estimated assuming cash flows for three years because market participants would not know about the next generation technology, the useful life of the acquired technology license is only two years.

  From this example, it is clear that the FASB anticipates that there will be circumstances in which the time over which market participants forecast an intangible asset to generate cash flows will differ from the actual useful life of that asset in the hands of a particular buyer. While this situation may be uncomfortable to many financial executives, the market participant assumptions will create scenarios such as this leading to a higher value under fair value that leads to unforeseen higher amortization expense in the short term.

1Staff Position on Statement No. 157 (FSP FAS 157-2), Financial Accounting Standards Board.
2Statement of Financial Accounting Standards No. 157, Fair Value Measurements, Financial Accounting Standards Board, para. 10.
3Ibid., para. 11

Available Medications For Herpes – STD Testing Centers Nashville

Herpes symptoms are unpleasant but the painful blisters can be treated with a topical cream which will soothe the pain and make them heal quicker. You may also be prescribed anti-viral tablets to either take 5 times a day when the virus is present or take regularly but in low doses throughout the year to prevent outbreaks (this will be recommended if you have more than 6 outbreaks per year). Herpes symptoms are fairly easy to recognize when people know what they’re looking for. There is some difference in expression of symptoms depending on type of herpes, or where the herpes infected the skin.

Medications are available to help relieve symptoms, reduce the risk of recurrences, and decrease the risk of transmitting herpes to others.
Valtrex (Valacyclovir ) is used to treat people with genital herpes who are currently having an outbreak. It can also be used to prevent an outbreak (suppressive therapy). Valacyclovir belongs to a class of medications known as antivirals. If you are taking valacyclovir for treatment of genital herpes, to lower the chance of giving herpes to your partner, it is important to follow safe sex practices even if there are no symptoms present. Valacyclovir hydrochloride is rapidly converted to acyclovir which has demonstrated antiviral activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) and varicella-zoster virus (VZV) both in vitro and in vivo. The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV.

Valtrex disrupts the process by which the herpes virus reproduces itself and spreads to other cells in the body. This helps to keep the virus inactive, or “sleeping.”.It is a drug that is changed in the body to its active ingredient which is what kills the virus. Valtrex may be used in combination with safe sex practices in patients with genital herpes to help reduce the risk of spreading the condition to others. Valtrex may also be used for cold sores (herpes simplex) or other conditions as determined by your doctor. Valtrex should not be taken for more than 1 day. The elderly and people with kidney problems may need a reduced dosage.

What To Avoid In Using Valtrex

Avoid while valtrex deacrease the age. Smith kline may cause any ingredient in intensity, inform your. Avoid letting infected areas come into contact with other people. Wash your hands frequently to prevent transmission. Avoid sexual activities or use condoms. The infected areas should not be touched by others.
Avoid touching an infected area and then touching your eyes. Avoiding these typical instigators might help prevent attacks.

What To Do

You should store valtrex away from heat, moisture, and light. Do not store in the bathroom. Store it at room temperature and away from excess heat and moisture (not in the bathroom). Throw away any medication that is outdated or no longer needed.